Geake, James B

Reid, David W

Currie, Bart

Bell, Scott C

Bright-Thomas, Rowland

Dewar, Jane

Holden, Steve

Simmonds, Nicholas

Gyi, Khin

Kenna, Dervla

Waters, Valerie

Jackson, Mary

O'Sullivan, Brian

Taccetti, Giovanni

Kolbe, John

O'Carroll, Mark

Campbell, Dee

Jaksic, Mirjana

Radhakrishna, Naghmeh

Kidd, Timothy J

Flight, William

2015-10-09

Several cases of Burkholderia pseudomallei infection in CF have been previously reported. We aimed to identify all cases globally, risk factors for acquisition, clinical consequences, and optimal treatment strategies. We performed a literature search to identify all published cases of B. pseudomallei infection in CF. In addition we hand-searched respiratory journals, and contacted experts in infectious diseases and CF around the world. Supervising clinicians for identified cases were contacted and contemporaneous clinical data was requested. 25 culture-confirmed cases were identified. The median age at acquisition was 21 years, mean FEV1 % predicted was 60 %, and mean BMI was 19.5 kg/m(2). The location of acquisition was northern Australia or south-east Asia for most. 19 patients (76 %) developed chronic infection, which was usually associated with clinical decline. Successful eradication strategies included a minimum of two weeks of intravenous ceftazidime, followed by a consolidation phase with trimethoprim/sulfamethoxazole, and this resulted in a higher chance of success when instituted early. Three cases of lung transplantation have been recorded in the setting of chronic B. pseudomallei infection. Chronic carriage of B. pseudomallei in patients with CF appears common after infection, in contrast to the non-CF population. This is often associated with an accelerated clinical decline. Lung transplantation has been performed in select cases of chronic B. pseudomallei infection.

Department of Respiratory Medicine, The Lyell-McEwin Hospital, Haydown Road, Elizabeth Vale, 5112, South Australia, Australia. james.geake@health.sa.gov.au..

The Prince Charles Hospital, Rode Road, Chermside, Brisbane, 4032, Australia. david.reid@qimrberghofer.edu.au.. QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane, 4006, Australia. david.reid@qimrberghofer.edu.au..

Menzies School of Health Research and Royal Darwin Hospital, Darwin, NT, Australia. bart.currie@menzies.edu.au..

The Prince Charles Hospital, Rode Road, Chermside, Brisbane, 4032, Australia. scott.bell@qld.health.gov.au.. QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane, 4006, Australia. scott.bell@qld.health.gov.au..

BMC Pulm Med . 2015 Oct 9:15:116. doi: 10.1186/s12890-015-0109-9.

https://pubmed.ncbi.nlm.nih.gov/26453341/?otool=iaurydwlib

https://hdl.handle.net/10137/5429

Adolescent

Adult

Anti-Bacterial Agents

Australasia

Ceftazidime

Child

Cystic Fibrosis

Europe

Female

Forced Expiratory Volume

Humans

Male

Melioidosis

North America

Retrospective Studies

Young Adult

Burkholderia pseudomallei

An international, multicentre evaluation and description of Burkholderia pseudomallei infection in cystic fibrosis.

Journal Article

Publication